Anzeige
Meldung des Tages: Europas Energie-Vorteil: Während Miner kämpfen: In Finnland entsteht der vielleicht billigste Bitcoin Europas

Palatin Technologies News

Aktie
WKN:  A41E9H ISIN:  US6960776010 US-Symbol:  PTN Branche:  Biotechnologie Land:  USA
22,22 $
+1,67 $
+8,13%
18,961 € 22:10:00 Uhr
Depot/Watchlist
Marktkapitalisierung *
331,16 Mio. €
Streubesitz
88,79%
KGV
-
Index-Zuordnung
-

Palatin Technologies News

17.02.26 - PR Newswire
Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update PR Newswire
06.11.25 - PR Newswire
Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity
Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-​Based Therapies for Obesity PR Newswire
06.11.25 - PR Newswire
Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering
Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering PR Newswire
22.09.25 - PR Newswire
Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim
Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim PR Newswire
08.08.25 - PR Newswire
Palatin Announces 1-for-50 Reverse Stock Split
Palatin Announces 1-for-50 Reverse Stock Split PR Newswire
15.07.25 - PR Newswire
Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity
Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity PR Newswire
14.05.25 - PR Newswire
Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update
Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update PR Newswire
09.05.25 - PR Newswire
Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025
Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025 PR Newswire
08.05.25 - PR Newswire
Palatin Technologies Announces Closing of Reduced Public Offering
Palatin Technologies Announces Closing of Reduced Public Offering PR Newswire
08.05.25 - PR Newswire
Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025
Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025 PR Newswire
07.05.25 - PR Newswire
Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice
Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice PR Newswire
07.05.25 - PR Newswire
Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice
Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice PR Newswire
07.05.25 - PR Newswire
Palatin Technologies Announces Pricing of up to $23 Million Public Offering
Palatin Technologies Announces Pricing of up to $23 Million Public Offering PR Newswire
05.05.25 - PR Newswire
Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy
Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-​Action Glaucoma Therapy PR Newswire
29.04.25 - PR Newswire
Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease
Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease PR Newswire

Newssuche

Videos

newspaper
20.04.26 +3,54%
Technical Trading: GBP Long im Trend
GBP/USD Long Typ: Open End Turbo WKN: VV7A4S Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »